Combining DNA Fragmentation Patterns and Protein Biomarkers, DELFI-Pro Outperforms Current Methods, Offering Hope for Timely Intervention
Scienceable.net — A landmark study in Cancer Discovery introduces a transformative blood test that detects ovarian cancer with unprecedented precision, addressing a critical gap in women’s healthcare. Developed by a global consortium of researchers, the DELFI-Pro test merges cutting-edge analysis of cell-free DNA (cfDNA) fragmentation patterns with protein biomarker quantification, achieving over 99% specificity and 72–100% sensitivity across cancer stages. This innovation could redefine screening protocols for a disease often diagnosed too late for effective treatment.
The Urgency of Early Detection
Ovarian cancer is the fifth leading cause of cancer-related deaths in women, with over 200,000 global fatalities annually. Symptoms like bloating or pelvic pain are easily overlooked, leading to 70% of cases being diagnosed at advanced stages (III/IV), where survival plummets to 31%. Current tools, such as transvaginal ultrasound and the CA-125 protein test, lack the sensitivity and specificity for population-wide screening. DELFI-Pro’s breakthrough lies in its ability to detect stage I cancers—when survival exceeds 90%—while minimizing false alarms.
The research analyzed 591 women across three cohorts: healthy individuals, those with benign ovarian masses, and ovarian cancer patients. Key results include:
- Stage-Specific Sensitivity:
- Stage I: 72% detected (vs. 34% for CA-125 alone).
- Stage II: 69% (vs. 62% for CA-125).
- Stage III: 87% (vs. 63% for CA-125).
- Stage IV: 100% (matching CA-125 but with fewer false positives).
- Discriminating Benign vs. Malignant Masses: The test differentiated benign growths (e.g., cysts, fibromas) from cancers with an AUC of 0.88, reducing unnecessary surgeries.
- Validation Across Populations: Performance held in independent U.S. and European cohorts, with 73% overall sensitivity and 81% sensitivity for aggressive high-grade serous ovarian cancer (HGSOC).
The Science Behind DELFI-Pro
- cfDNA Fragmentomics: Tumors shed DNA fragments into the bloodstream with distinct size and distribution patterns. DELFI-Pro uses low-coverage whole-genome sequencing (~2x) to analyze these fragments across 473 genomic regions. Cancer DNA exhibits chaotic fragmentation, while healthy DNA is orderly.
- Protein Biomarkers: The test integrates levels of CA-125 and HE4—proteins elevated in ovarian cancer—adding complementary diagnostic power.
- Machine Learning: A penalized logistic regression model combines 20+ features (fragment ratios, chromosomal gains/losses, protein levels) to generate a risk score.
Notably, the test avoids pitfalls of mutation-based liquid biopsies, which are confounded by “noise” from non-cancerous cell changes.
Real-World Implication
- Reduced False Positives: At >99% specificity, DELFI-Pro’s false-positive rate (FPR) in simulations was 0.95%, versus 3–20% for CA-125/HE4 alone. This could prevent thousands of unnecessary invasive procedures.
- Higher Predictive Value: Monte Carlo modeling of 100,000 women showed DELFI-Pro’s positive predictive value (PPV) was 23.6%—more than double CA-125’s 9.17%—making population screening feasible.
- Cost-Effective Design: The test requires only 3 mL of blood and uses widely available sequencing tools, enabling scalability.
“This is about intercepting cancer early, when surgeries and therapies can cure,” said senior author Dr. Victor Velculescu of Johns Hopkins. “The combination of cfDNA and proteins creates a biological ‘fingerprint’ that’s hard to miss.”
Challenges and Next Steps
- Subtype Limitations: Detection was lower for mucinous (65% AUC) and clear cell (77% AUC) cancers. Adding subtype-specific biomarkers may improve accuracy.
- Survival Data Pending: While DELFI-Pro enables earlier diagnosis, a phase III trial (NCT04971421) is ongoing to confirm if it translates to mortality reduction.
- Integration into Care: Researchers envision DELFI-Pro as a first-line screen for high-risk groups (e.g., BRCA carriers) and a triage tool for women with pelvic masses.
Behind the Research
The study involved institutions like Johns Hopkins, the Netherlands Cancer Institute, and the University of Pennsylvania. Notably, some authors hold patents or equity in DELFI Diagnostics, a startup commercializing the technology. Funding came from the Gray Foundation, SU2C, and the NIH, among others.
The Bottom Line:
DELFI-Pro represents a paradigm shift in ovarian cancer diagnostics. By catching tumors earlier and reducing unnecessary interventions, it could save countless lives—and pave the way for similar multi-analyte approaches in other hard-to-detect cancers
Citation:
Medina, J. E., Annapragada, A. V., Lof, P., et al. (2025). Early Detection of Ovarian Cancer Using Cell-Free DNA Fragmentomes and Protein Biomarkers. Cancer Discovery, 15(1), 105–118. https://doi.org/10.1158/2159-8290.CD-24-0393
For more breakthroughs in cancer research, follow Scienceable.net.
